PAG
MDGL icon

Private Advisor Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Private Advisor Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-536
Closed -$312K – 2793
2025
Q4 		$312K Buy
+536
New +$274K ﹤0.01% 2134
2020
Q3 		– Sell
-52
Closed -$6K – 2676
2020
Q2 		$6K Buy
+52
New +$5.11K ﹤0.01% 3170

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Private Advisor Group's MDGL Position: Q1 2026 in Review

Private Advisor Group sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 536 shares — an estimated $312K sold.

Private Advisor Group first reported a position in MDGL in Q2 2020 and held it in 2 quarters. The position peaked at $312K in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Private Advisor Group reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Private Advisor Group sold 536 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $312K.
  • Private Advisor Group first reported a position in Madrigal Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Private Advisor Group's Madrigal Pharmaceuticals position peaked at $312K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.